Axovant Announces Second Fiscal Quarter 2018 Financial Results and Corporate Updates
November 07, 2018 16:05 ET
|
Axovant Sciences Ltd.
First patient dosed in clinical study of AXO-Lenti-PD, a novel gene therapy for treatment of Parkinson’s diseaseExpanded pipeline of gene therapies with in-licensing of AXO-AAV-OPMD for treatment of...
Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, a Novel Gene Therapy for Patients With Parkinson’s Disease
October 25, 2018 02:00 ET
|
Axovant Sciences Ltd.
Initial data from the first cohort expected in first half of 2019 BASEL, Switzerland, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON), a company developing innovative gene...
Axovant Announces Data to be Presented at the Annual Congress of the European Society of Gene and Cell Therapy
October 09, 2018 09:02 ET
|
Axovant Sciences Ltd.
BASEL, Switzerland, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON), a gene therapy company developing innovative treatments for debilitating neurologic and neuromuscular diseases,...
Axovant to Present at Two Upcoming Investor Conferences
September 20, 2018 07:00 ET
|
Axovant Sciences Ltd.
BASEL, Switzerland, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the...
Axovant to Present at Upcoming Investor Conferences
August 29, 2018 07:00 ET
|
Axovant Sciences Ltd.
BASEL, Switzerland, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will participate in two upcoming investor...
Axovant Announces First Fiscal Quarter 2018 Financial Results and Corporate Update
August 07, 2018 16:05 ET
|
Axovant Sciences Ltd.
Pipeline expanded with gene therapy technologies including AXO-Lenti-PD for treatment of Parkinson’s Disease and AXO-AAV-OPMD for treatment of oculopharyngeal muscular dystrophy Ilise Lombardo, MD,...
Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD Program for Treatment of Oculopharyngeal Muscular Dystrophy and Broader Platform Collaboration with Benitec Biopharma
July 08, 2018 20:18 ET
|
Axovant Sciences Ltd.
License grants Axovant worldwide rights to AXO-AAV-OPMD utilizing proprietary Silence-and-Replace technology, which suppresses mutant protein production while restoring expression of functional...
Axovant to Present at First Annual Roivant Pipeline Day
June 18, 2018 08:30 ET
|
Axovant Sciences Ltd.
BASEL, Switzerland, June 18, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the first...
Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease from Oxford BioMedica and Announces Key Leadership Team Addition
June 06, 2018 02:00 ET
|
Axovant Sciences Ltd.
Exclusive worldwide license to lentiviral vector gene therapy constitutes the first transaction of Axovant’s 2018 pipeline expansionFraser Wright, Co-Founder and former Chief Technology Officer of...
Axovant to Present at Two Upcoming Investor Conferences
May 31, 2018 07:00 ET
|
Axovant Sciences Ltd.
BASEL, Switzerland, May 31, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the...